$ABBV released its Q4 2024 earnings, revealing adjusted EPS of $2.16, missing estimates by $0.10, but total revenues of $15.10B surpassed expectations, showing a 6.1% growth. Risks include ongoing biosimilar pressures for Humira, while highlights include strong performances from Skyrizi and Rinvoq, contributing to a 22% revenue boost. Future outlook suggests robust mid-single-digit revenue growth for 2025 with anticipated increases from their ex-Humira platform. For more details, check http://valueverge.com/ABBV.
